Fort
Lee, N.J. March 31, 2015 Herborium® Group, Inc. (OTC Pink: HBRM),
www.Herborium.com, a Botanical Therapeutics® Company and the
provider of unique all botanical medicinal products (Botanical
Therapeutics®) that target dermatological problems such as acne, and
other major health and wellness concerns reports that its sales for
the First Quarter of 2015 grew by 21% in comparison to the same
period of 2014. This sales growth places the present run rate for
AcnEase® sales for 2015 to approach $1,000,000.
This
Quarter is also the 9th consecutive quarter of double digit sales
growth for Herborium Group, and 5th consecutive quarter with an
increase in the average value of the unit sales per customer. We
attribute this increase to a significant expansion in the Company’s
international sales especially in the UK and France. The value of an
average international order is about 20% higher in comparison to a
domestic order, and also has a higher margin.
Herborium
launched an independent French platform www.acnease.fr in February
2015 and the initial sales on this platform has exceeded
expectations. Mobile versions of www.acnease.com launched in 2014
and a mobile version of www.acnease.fr also growing and presently
account for about 25% of Internet orders. In 2014, “mobile”
orders accounted for approximately 18 % of Internet orders First
Quarter of 2015 has also shown an increase in distributor’s
participation in revenues growing by 20% in comparison to the same
period of 2014. This is a testament of a growing wholesale market
interest for Herborium’s products.
The
steady growth in revenues, and other financial indicators such as
market share, gross margin and expending distribution channels put
the Company closer to executing the development plan and up listing
plan announced for 2015.
About
Herborium Group, Inc.
Herborium
Group, Inc., a botanical therapeutics® company that develops,
license and markets proprietary, botanical based medicinal products
to consumers and healthcare professionals. The Company business model
focuses on emerging market opportunities spearheaded by the growth of
a new market sector located between high-cost, high-risk, ethical
pharmaceuticals and commoditized classic nutraceuticals
(supplements). The Company uses clinical validation and a proactive
regulatory strategy based on the FDA Guidance for Industry: Botanical
Drug Products (FDA Guidance 2004) to establish and maintain a
differential advantage. Herborium has secured a pipeline of
botanical ingredients based products in the areas of dermatological
needs, wellness and energy, prostate health, women’s health and
selected sexual disorders resulting from cardiovascular disease, use
of anti-depressants, diabetes, surgical procedures, and other
problems. Herborium Group sells its products in the United States,
Canada, the United Kingdom, and continental Europe as well as in
Australia through a network of distributors, specialty retailers, and
e-commerce. For more information, please visit www.herborium.com,
www.acnease.com and www.acnease.fr
Safe
Harbor Statement: This release contains forward-looking statements
with respect to the results of operations and business of Herborium
Group, Inc., which involves risks and uncertainties. The Company's
actual future results could materially differ from those discussed.
The Company intends that such statements about the Company's future
expectations, including future revenues and earnings, and all other
forward looking statements be subject to the "Safe Harbors"
provision of the Private Securities Litigation Reform Act of 1995.
Contact
Information:Herborium Group, Inc.
Email:
InvestorsRelations@Herborium.com
